MX2021013356A - Tratamiento y prevencion de enfermedades metabolicas. - Google Patents

Tratamiento y prevencion de enfermedades metabolicas.

Info

Publication number
MX2021013356A
MX2021013356A MX2021013356A MX2021013356A MX2021013356A MX 2021013356 A MX2021013356 A MX 2021013356A MX 2021013356 A MX2021013356 A MX 2021013356A MX 2021013356 A MX2021013356 A MX 2021013356A MX 2021013356 A MX2021013356 A MX 2021013356A
Authority
MX
Mexico
Prior art keywords
metabolic diseases
prevention
treatment
methods
agents
Prior art date
Application number
MX2021013356A
Other languages
English (en)
Spanish (es)
Inventor
Stuart Alexander Cook
Sebastian Schaefer
Anissa Anindya Widjaja
Brijesh Kumars Singh
Original Assignee
Singapore Health Serv Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1906291.8A external-priority patent/GB201906291D0/en
Priority claimed from GBGB2001013.8A external-priority patent/GB202001013D0/en
Priority claimed from GBGB2001896.6A external-priority patent/GB202001896D0/en
Priority claimed from GBGB2002030.1A external-priority patent/GB202002030D0/en
Application filed by Singapore Health Serv Pte Ltd filed Critical Singapore Health Serv Pte Ltd
Publication of MX2021013356A publication Critical patent/MX2021013356A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2073—IL-11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5431—IL-11
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2021013356A 2019-05-03 2020-05-01 Tratamiento y prevencion de enfermedades metabolicas. MX2021013356A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB1906291.8A GB201906291D0 (en) 2019-05-03 2019-05-03 Treatment and prevention of metabolic diseases
GBGB1906597.8A GB201906597D0 (en) 2019-05-03 2019-05-10 Treatment and prevention of metabolic diseases
GBGB2001013.8A GB202001013D0 (en) 2020-01-24 2020-01-24 Treatment and prevention of metabolic diseases
GBGB2001896.6A GB202001896D0 (en) 2020-02-12 2020-02-12 Treatment and prevention of metabolic diseases
GBGB2002030.1A GB202002030D0 (en) 2020-02-14 2020-02-14 Treatment and prevention of metabolic diseases
PCT/EP2020/062193 WO2020225147A1 (en) 2019-05-03 2020-05-01 Treatment and prevention of metabolic diseases

Publications (1)

Publication Number Publication Date
MX2021013356A true MX2021013356A (es) 2022-03-11

Family

ID=73051262

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013356A MX2021013356A (es) 2019-05-03 2020-05-01 Tratamiento y prevencion de enfermedades metabolicas.

Country Status (13)

Country Link
US (2) US11813311B2 (cg-RX-API-DMAC7.html)
EP (1) EP3962936A1 (cg-RX-API-DMAC7.html)
JP (1) JP7595028B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220050087A (cg-RX-API-DMAC7.html)
CN (1) CN114364693A (cg-RX-API-DMAC7.html)
AU (1) AU2020268619B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021021921A2 (cg-RX-API-DMAC7.html)
CA (1) CA3146344A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002878A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021013356A (cg-RX-API-DMAC7.html)
PH (1) PH12021552763A1 (cg-RX-API-DMAC7.html)
TW (1) TW202108606A (cg-RX-API-DMAC7.html)
WO (1) WO2020225147A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220050087A (ko) * 2019-05-03 2022-04-22 싱가포르 헬스 서비시즈 피티이 엘티디 대사성 질환의 치료 및 예방
EP4110317B1 (en) 2020-02-28 2025-11-19 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2021251903A1 (en) * 2020-06-09 2021-12-16 Temasek Life Sciences Laboratory Limited Automated disease detection system
CN113041248A (zh) * 2021-04-26 2021-06-29 北京亿药科技有限公司 Ravoxertinib在制备预防和/或治疗非酒精性脂肪性肝病或肝炎药物中的应用
WO2023006765A1 (en) * 2021-07-26 2023-02-02 Boehringer Ingelheim International Gmbh Treatment and prevention of alcoholic liver disease
JP2024532620A (ja) * 2021-08-30 2024-09-05 ラッセン・セラピューティクス1・インコーポレイテッド 抗IL-11Rα抗体
CN114081882B (zh) * 2021-11-15 2023-01-10 中国科学院深圳先进技术研究院 一种a-fabp蛋白抑制剂及其应用
GB202218388D0 (en) 2022-12-07 2023-01-18 Vvb Bio Pte Ltd GP130 antigen-binding molecules
EP4702047A1 (en) 2023-04-25 2026-03-04 VVB Bio Pte. Ltd. Anti il-11 antibody
WO2024259282A2 (en) * 2023-06-15 2024-12-19 The Board Of Trustees Of The Leland Stanford Junior University Interleukin 11 polypeptides and methods of use
GB202311050D0 (en) 2023-07-19 2023-08-30 Vvb Bio Pte Ltd GP130 antigen-binding molecules
GB202405551D0 (en) 2024-04-19 2024-06-05 Vvb Bio Pte Ltd Combination treatment
GB202408044D0 (en) 2024-06-06 2024-07-24 Vvb Bio Pte Ltd gp130 antigen-binding molecules
WO2026159121A1 (en) 2025-01-22 2026-07-30 VVB Bio Pte. Ltd. Bispecific molecules

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
ES2093562B1 (es) 1995-05-26 1997-07-01 Univ Santiago Compostela Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
US6649192B2 (en) 1996-07-29 2003-11-18 Universidade De Santiago De Compostela Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CA2237915A1 (en) 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
EP1311277A4 (en) 2000-07-18 2004-08-25 Joslin Diabetes Center Inc METHODS OF FIBROSIS MODULATION
AU2002362088A1 (en) * 2001-12-06 2003-06-23 Catholic University Method and composition for inducing weight loss
US8182814B2 (en) 2007-10-26 2012-05-22 Csl Limited Methods of treating inflammatory airway conditions by inhibition of IL-11 activity
CA2703544C (en) 2007-10-26 2016-01-05 Manuel Baca Cytokine muteins
US8518888B2 (en) 2008-10-14 2013-08-27 Csl Limited Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R
CN105859889B (zh) * 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
PT2953971T (pt) * 2013-02-07 2023-05-02 Csl Ltd Proteínas de ligação à il-11r e suas utilizações
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
WO2016025313A1 (en) 2014-08-11 2016-02-18 Samir Patel Methods for treating or preventing ophthalmological conditions
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
WO2017141032A1 (en) 2016-02-15 2017-08-24 Oxford University Innovation Limited Treatment of fibrotic disorders
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
US20180186871A1 (en) 2016-12-16 2018-07-05 Singapore Health Services Pte Ltd. Il-11 antibodies
GB201621431D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore The Decoy cytokine receptor
GB201806918D0 (en) 2018-04-27 2018-06-13 Enleofen Bio Pte Ltd Combination treatment for eye fibrosis
GB201809699D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
GB201809700D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
KR20220050087A (ko) * 2019-05-03 2022-04-22 싱가포르 헬스 서비시즈 피티이 엘티디 대사성 질환의 치료 및 예방

Also Published As

Publication number Publication date
JP7595028B2 (ja) 2024-12-06
US20210177940A2 (en) 2021-06-17
AU2020268619B2 (en) 2026-03-05
CL2021002878A1 (es) 2022-10-07
CA3146344A1 (en) 2020-11-12
US11813311B2 (en) 2023-11-14
AU2020268619A1 (en) 2021-12-16
BR112021021921A2 (pt) 2021-12-28
CN114364693A (zh) 2022-04-15
TW202108606A (zh) 2021-03-01
US20240156913A1 (en) 2024-05-16
EP3962936A1 (en) 2022-03-09
JP2022531591A (ja) 2022-07-07
WO2020225147A1 (en) 2020-11-12
PH12021552763A1 (en) 2022-07-04
US20200384083A1 (en) 2020-12-10
KR20220050087A (ko) 2022-04-22

Similar Documents

Publication Publication Date Title
CL2021002878A1 (es) Tratamiento y prevención de enfermedades metabólicas
CL2021002212A1 (es) Tratamiento de lesión renal
CL2021001903A1 (es) Tratamiento de la hepatotoxicidad
CL2020002019A1 (es) Composiciones para modular la expresión de c9orf72. (divisional solicitud 201803582)
SA521422031B1 (ar) مركبات 2 – فورميل – 3 – هيدروكسي فينيلوكسي ميثيل قادرة على تعديل الهيموجلوبين
MX379543B (es) Purinonas como inhibidores de proteasa específica de ubiquitina 1.
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
MX2020006128A (es) Inhibidores de la proteina de activacion de fibroblastos.
MX2018006223A (es) Moduladores de ror-gamma.
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
MX390535B (es) Compuestos de amino-triazolopiridina y su uso en el trataniento del cancer.
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
MX2016010034A (es) Inhibidores de dihidropirrolopiridina de receptor huerfano relacionado-gamma.
MX2021000142A (es) Composiciones y metodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas.
PH12022550843A1 (en) Thienopyrimidones as trpa1 inhibitors
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
MX2021004819A (es) Composiciones y metodos para tratar lesiones cerebrales.
UY37466A (es) N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
PH12020551573A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
MX2020009566A (es) Compuestos como moduladores de la se?alizacion de tlr2.
CR20210499A (es) Compuestos y composiciones como moduladores de la señalización de tlr
PH12021552133A1 (en) Aromatic derivatives, preparation methods, and medical uses thereof